胰腺癌对RAS(ON)多选择性抑制剂daraxonrasib获得性耐药机制指导联合治疗策略
本研究通过靶向测序44例经daraxonrasib单药治疗的RAS突变转移性胰腺癌患者的配对循环肿瘤DNA,发现59%出现RAS通路获得性基因组改变,最常见为突变KRAS扩增(36%)。临床前模型验证了耐药机制,并提示联合DNA损伤应答、RTK或突变选择性RAS(ON) G12D抑制剂zoldonrasib可克服耐药。
要点
- daraxonrasib单药治疗RAS突变转移性胰腺癌后,59%患者出现RAS通路获得性基因组改变。
- 突变KRAS扩增是最常见的耐药机制,见于36%的患者。
- 联合DNA损伤应答、RTK或zoldonrasib可逆转耐药,支持联合治疗策略。
核心结论
- 多数daraxonrasib获得性耐药机制通过重新激活RAS通路信号传导,为胰腺癌联合治疗策略提供依据。
研究设计与样本
- 对1/2期临床试验中44例经daraxonrasib单药治疗的RAS突变转移性胰腺癌患者,进行治疗前和治疗结束配对循环肿瘤DNA的800余基因靶向测序。
- 利用人源和鼠源胰腺癌临床前模型验证耐药机制并探索联合治疗。
主要发现
- 治疗中出现的RAS信号通路基因组改变见于26/44(59%)患者。
- 突变KRAS扩增见于16/44(36%)患者,RTK通路改变4/44(9%),MAPK通路改变11/44(25%),PI3K通路改变4/44(9%)。
- 未观察到获得性KRAS二次突变,与突变选择性KRAS G12C(OFF)抑制剂的耐药谱不同。
- 临床前模型再现突变KRAS和MYC扩增及RTK上调等耐药机制。
关键数值与推荐
- daraxonrasib联合DNA损伤应答靶向药、RTK靶向药或突变选择性RAS(ON) G12D抑制剂zoldonrasib在临床前模型中可避免耐药。
临床怎么用
- 对daraxonrasib治疗后进展的胰腺癌患者,可考虑检测RAS通路获得性改变(如突变KRAS扩增)以指导联合治疗。
- 联合DNA损伤应答、RTK或zoldonrasib等策略值得进一步临床研究。
局限性
- 耐药机制基于44例患者的循环肿瘤DNA测序,样本量有限。
- 联合治疗克服耐药的证据主要来自临床前模型,尚未在临床试验中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Daraxonrasib is an orally bioavailable RAS(ON) multi-selective tri-complex inhibitor of the oncogenic mutant and wild-type variants of N, H and KRAS. We previously reported encouraging efficacy in a phase 1/2 clinical trial evaluating daraxonrasib monotherapy at clinically active dose levels in patients with previously treated, RAS mutant metastatic pancreatic adenocarcinoma (PDAC), providing the basis for confirmatory evaluation in the randomized phase 3 RASolute 302 clinical trial. Here we report mechanisms of acquired resistance to daraxonrasib monotherapy observed through targeted sequencing of over 800 genes in paired pretreatment and end of treatment circulating tumor DNA samples from 44 patients in the phase 1/2 clinical trial. Treatment-emergent genomic alterations in the RAS signaling pathway were observed in more than half (26 of 44; 59%) of these patients, including, most notably, mutant KRAS amplifications in one-third (16 of 44; 36%), as well as alterations in receptor tyrosine kinase (RTK) (4 of 44; 9%), MAPK (11 of 44; 25%) and PI3K (4 of 44; 9%) pathways. Notably, no acquired secondary KRAS mutations were observed, distinct from resistance profiles of mutant-selective KRAS G12C(OFF) inhibitors. To corroborate these clinical findings, we found, or mechanistically established, concordant mechanisms of daraxonrasib resistance in human and murine preclinical models of PDAC, including mutant KRAS and MYC amplification and RTK upregulation, with these alterations guiding various combination therapy concepts. Notably, daraxonrasib combined with agents targeting DNA damage response, RTKs or the mutant-selective RAS(ON) G12D inhibitor zoldonrasib averted resistance in preclinical models. Collectively, these results show that most daraxonrasib genomic resistance mechanisms drive reactivation of RAS pathway signaling and guide potential combination strategies in PDAC for further investigation.
引用
- Aronchik I, Kar S, Zhuang Y, et al. Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer. Nat Med. 2026. PMID: 42581230. doi:10.1038/s41591-026-04537-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。